Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL [clinicaltrials_resource:be54c0ec6552d7ffc16f9e02c6b07826]
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission [clinicaltrials:NCT00093470]Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant [clinicaltrials:NCT00096161]Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia [clinicaltrials:NCT00217646]clinicaltrials:NCT00351975Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase [clinicaltrials:NCT00383474]Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia [clinicaltrials:NCT00392353]clinicaltrials:NCT00416598Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders [clinicaltrials:NCT00588991]clinicaltrials:NCT00658814Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [clinicaltrials:NCT01130506]Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia [clinicaltrials:NCT01132586]Veliparib and Temozolomide in Treating Patients With Acute Leukemia [clinicaltrials:NCT01139970]Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia [clinicaltrials:NCT01168219]Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia [clinicaltrials:NCT01249430]Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers [clinicaltrials:NCT01254578]Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia [clinicaltrials:NCT01260714]clinicaltrials:NCT01361464Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [clinicaltrials:NCT01371981]Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia [clinicaltrials:NCT01420926]Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia [clinicaltrials:NCT01627041]clinicaltrials:NCT01806571Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia [clinicaltrials:NCT01870596]Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant [clinicaltrials:NCT02038153]Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes [clinicaltrials:NCT02044796]clinicaltrials:NCT02129101
condition [clinicaltrials_vocabulary:condition]
Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL [clinicaltrials_resource:be54c0ec6552d7ffc16f9e02c6b07826]
Bio2RDF identifier
be54c0ec6552d7ffc16f9e02c6b07826
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:be54c0ec6552d7ffc16f9e02c6b07826
identifier
clinicaltrials_resource:be54c0ec6552d7ffc16f9e02c6b07826
title
Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL
@en
label
Adult Acute Myeloid Leukemia W ...... 4c0ec6552d7ffc16f9e02c6b07826]
@en